As per Future Market Insights’ recent industry analysis, the Global Proton Pump Inhibitors Industry is poised for substantial expansion at a notable CAGR of 5.2%. By 2033, it is anticipated to elevate from a 2022 valuation of US$ 2.8 Billion to an impressive US$ 4.9 Billion.”
Gastrointestinal Health Propels Global Proton Pump Inhibitors Industry: Addressing the Rise in Gastrointestinal Disorders
The surge in the global Proton Pump Inhibitors (PPIs) Market can be attributed to the growing prevalence of gastrointestinal disorders. A range of conditions including gastroesophageal reflux disease (GERD), peptic ulcers, and Helicobacter pylori infections is on the rise worldwide. PPIs have emerged as the go-to choice for effectively managing and treating these disorders. With the increasing number of individuals affected by gastrointestinal issues, the demand for PPIs as the primary therapeutic solution is on the upswing. This trend underscores the pivotal role PPIs play in alleviating the escalating burden of gastrointestinal disorders and enhancing patient outcomes and quality of life.
Request a Sample Copy of the Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-17480
Strong research and development (R&D) activities are a key driver of the Proton Pump Inhibitor (PPI) market. Ongoing R&D efforts in the field of gastroenterology and drug development have led to the introduction of new and improved PPI formulations. These innovations, including novel drug delivery systems and enhanced efficacy profiles, attract healthcare professionals and patients alike. The continuous pursuit of advancements in PPI medications not only improves treatment options but also addresses the evolving needs of patients with gastrointestinal disorders. Consequently, the market for PPIs is propelled forward by the commitment to R&D, fostering innovation, and ultimately providing better therapeutic solutions for patients worldwide.
Top Highlights by FMI’s Analysis:
- Omeprazole dominates the Proton Pump Inhibitors (PPIs) market, holding a significant market share of 28.5% in 2022. This leading position is driven by various factors, including its widespread availability, proven efficacy, and comparatively lower cost compared to other PPI drugs.
- The oral route of administration holds the leading position with a market share of 66.3% in 2022. Oral administration is the preferred method for delivering Proton Pump Inhibitors due to its convenience, ease of use, and high patient acceptance. It allows for effective systemic delivery of the medication, contributing to its dominant position in the market.
- Capsules are the leading dosage form with a market share of 39.2% in the global Proton Pump Inhibitors industry in 2022. Capsules offer advantages such as easy swallowing, accurate dosing, and protection of the medication from degradation. Healthcare professionals and patients for their convenience and effectiveness in delivering Proton Pump Inhibitors for treatment prefer them.
- Generics held a 74.3% market value share in 2022 in the global Proton Pump Inhibitors industry based on prescription type. Generic Proton Pump Inhibitors have gained prominence due to their cost-effectiveness, comparable efficacy, and availability as alternatives to brand-name medications.
- North America leads the global market in terms of region accounting for 38.8% market share in 2022. This is attributed to factors such as the high prevalence of gastrointestinal disorders, well-established healthcare infrastructure, robust research and development activities, and strong market presence of key pharmaceutical companies.
Methodology Details Just a Click Away!
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-17480
Competitive Landscape:
The market players active within this industry space are undertaking the launch of new products to continue maintaining their market share in the global market.
- On April 2022, Daewon Pharmaceutical launched Escorten, its inaugural proton-pump inhibitor (PPI) treatment, utilizing 10mg of esomeprazole magnesium trihydrate, effectively addressing gastric mucosal lesions in acute and chronic gastritis in Korea.
- On March 25, 2021, Xiromed LLC, a generic division of Insud Pharmaceuticals, launched Omeprazole delayed-release capsules, 20mg, as a cost-effective alternative to Prilosec®. CEO Narasimhan Mani expressed their commitment to expanding the product portfolio.
Major Players are:
AstraZeneca, Bayer AG, Cadila Pharmaceuticals, Eisai Inc., GlaxoSmithKline PLC, Pfizer Inc., Takeda Pharmaceuticals, Sanofi SA, Perrigo Company PLC, Dr. Reddy’s Laboratories, Redhill Pharma Limited, Cipla Limited
What Does the Report Cover?
Future Market Insights offers a unique perspective and actionable insights on the Proton Pump Inhibitors industry in its latest study, presenting a historical demand assessment of 2017 to 2022 and projections for 2023 to 2033. The global Proton Pump Inhibitors market is segmented in detail to cover every market aspect and present a complete market intelligence approach to the reader.
The research study is based on the Proton Pump Inhibitors industry by drug type (omeprazole, pantoprazole, rabeprazole, dexlansoprazole, lansoprazole, esomeprazole, and others), by route of administration (oral, and injectable), by dosage form (tablet, capsules, injection, and others), by prescription type (branded, and generics), by indication (gastroesophageal reflux disease, heartburn, peptic ulcer, and others), by distribution channel (retail pharmacies, hospital pharmacies, drug stores, and specialty clinics), and across 7 regions of the world.
Level Up Your Market Understanding – Buy Now!
https://www.futuremarketinsights.com/checkout/17480
Key Segmentation:
By Drug Type:
- Esomeprazole
- Omeprazole
- Dexlansoprazole
- Pantoprazole
- Rabeprazole
- Lansoprazole
- Others
By Route of Administration:
- Oral
- Injectable
By Dosage Form:
- Tablet
- Capsules
- Injection
- Others
By Prescription:
- Branded
- Generics
By Indication:
- Gastroesophageal Reflux Disease
- Heartburn
- Peptic ulcers
- Others
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Speciality Clinics
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
